FDA Approves Johnson & Johnson’s Advanced Bladder Cancer Drug

By John F. Heerdink, Jr.
According to The American Cancer Society’s website estimates for bladder cancer in the United States for 2019 are about 80,470 new cases of bladder cancer (about 61,700 in men and 18,770 in women and about 17,670 deaths from bladder cancer (about 12,870 in men and 4,800 in women. The rates of new bladder cancers and deaths linked to bladder cancer and have been dropping slightly in women in recent years. In men, incidence rates have been decreasing, but death rates have been stable. Bladder cancer is also the fourth most common cancer in men, but it’s less common in women. Recently, Johnson & Johnson’s drug Balversa, the first targeted therapy for advanced bladder cancer, gained U.S Food and Drug Administration approval. As reported, J&J stated the drug will be priced from $10,080 to $22,680 for a 28-day supply, depending on the dose. The drug can reportedly be used by patients whose cancer has advanced during the chemotherapy or having specific genetic alterations known as FGFR3 or FGFR2. Balversa acts as FGFR inhibitors, that hinders the growth factor receptors leading in cell growth and division. The drug is chemically known as erdafitinib. Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. Stay Informed! Stay Competitive! Join us at Vista Partners! It’s FREE to receive email updates.
week 3(6)

J&J wins U.S. FDA approval for bladder cancer drug

The list price of the drug, known chemically as erdafitinib, will range between $10,080 to $22,680 for a 28-day supply, depending of the dose, J&J said. Balversa is the first approved drug in a class known as FGFR inhibitors that targets growth factor receptors involved in cell growth and division… in.finance.yahoo.com
Read Full Article


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us